Antibody–drug conjugates (ADCs) combine the high specificity of monoclonal antibodies with the high potency of small-molecule cytotoxins to achieve targeted tumor cell killing, thereby improving efficacy while minimizing systemic toxicity. Compared with unconjugated antibodies or fragments, ...
Topic
ADC
Techniques for detecting, quantifying and localizing antigens and antibodies — ELISA, Western blotting, immunohistochemistry and flow cytometry. Below are the protocols, FAQs and technical articles in our knowledge base tagged with this topic.
4 resources · protocols, FAQs & articles
Antibody–drug conjugates (ADCs) consist of three components: a monoclonal antibody, a linker, and a cytotoxic payload. The antibody is responsible for recognizing tumor-associated antigens, the payload is responsible for killing cells, and the linker determines whether the payload can be ...
Antibody–drug conjugates (ADCs) combine the high specificity of monoclonal antibodies with the high potency of small-molecule cytotoxins to achieve targeted tumor cell killing, thereby improving efficacy while minimizing systemic toxicity. Compared with unconjugated antibodies or fragments, ...
Antibody-coupled drug ADCs are a hot frontier in cancer therapy, providing a targeted therapy approach that combines the specificity of monoclonal antibodies with the potency of cytotoxic agents.
Related topics
Techniques often explored alongside immunological experiments.